Other studies have reported 64Cu-DOTA-trastuzumab PET/CT and MRI for establishing predicting model of neoadjuvant response in HER2-positive breast cancer; using 18F-FES PET/CT for predicting the chemotherapy efficacy of MBC [83], or using FDG PET/CT to screen candidates for sentinel lymph node biopsy or axillary lymph node dissection [84]. Here, ERBB2 is linked to breast carcinoma.